drugset / Trial / NCT02839135

A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.

NCT02839135

Phase 1 Completed 128 enrolled GlaxoSmithKline
RandomizedCrossoverSingle-blindOther

Summary

In this comparative bioavailability and in vivo skin adhesion study, the impact of minor changes in qualitative composition of polyiso-Butylenes (PIB) from a different supplier and change of the manufacturing line of the micro porous membrane will be tested.

Timeline

Start
2016-05-13
Primary completion
2016-08-01
Completion
2016-08-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Scopolamine Unknown 1.5 mg Other

Indications